"Dibenzocycloheptenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of tricyclic hydrocarbons whose members include many of the commonly used tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC).
| Descriptor ID |
D003986
|
| MeSH Number(s) |
D02.455.426.559.847.181.384 D04.615.181.384
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dibenzocycloheptenes".
Below are MeSH descriptors whose meaning is more specific than "Dibenzocycloheptenes".
This graph shows the total number of publications written about "Dibenzocycloheptenes" by people in this website by year, and whether "Dibenzocycloheptenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dibenzocycloheptenes" by people in Profiles.
-
Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013 Nov-Dec; 36(6):223-38.
-
Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option? Expert Rev Neurother. 2011 Jul; 11(7):989-1006.
-
A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009 Jun; 32(3):274-9.
-
Autophagy induced by farnesyltransferase inhibitors in cancer cells. Cancer Biol Ther. 2008 Oct; 7(10):1679-84.
-
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008 Sep; 22(9):1707-11.
-
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20; 25(21):3137-43.
-
Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15; 110(6):2102-9.
-
A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics. 2006 Dec; 62(4):986-95.
-
Properties of the permeability transition in VDAC1(-/-) mitochondria. Biochim Biophys Acta. 2006 May-Jun; 1757(5-6):590-5.
-
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer. 2006 Jan 15; 106(2):346-52.